Sign in
CompletedNo phase

Inhibin B/FSH Ratio as a Predictor of Testicular Pathology in NOA

Key facts

Who runs it
Elazıg Fethi Sekin Sehir Hastanesi
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
73 people enrolled
Started
10 Jan 2026
Ended
5 Feb 2026
Type of study
Observational, 5 groups
Record updated
17 February 2026

Who can take part

Age
18 years and older
Sex
Men only
Healthy volunteers
Cannot take part
Show the full registry criteria (6)Hide the full registry criteria

Who can take part

  • Male patients who underwent micro-TESE for non-obstructive azoospermia
  • Available histopathological evaluation of testicular tissue
  • Available preoperative serum hormone measurements (FSH, LH, testosterone, Inhibin B)

Who cannot take part

  • Previous testicular malignancy
  • History of chemotherapy or radiotherapy affecting spermatogenesis
  • Incomplete clinical, hormonal, or histopathological data

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This retrospective observational study evaluated the diagnostic and predictive value of serum Inhibin B (INHB), follicle-stimulating hormone (FSH), and the INHB/FSH ratio in differentiating histopathological subtypes of non-obstructive azoospermia (NOA) in men undergoing microdissection testicular sperm extraction (micro-TESE). Seventy-three patients treated at a single tertiary referral center between January 2023 and September 2025 were included. Hormonal parameters were assessed preoperatively, and histopathological findings were categorized into five groups (SCOS, EMA, LMA, HSG, NS). The INHB/FSH ratio demonstrated significant discriminative ability across histopathological patterns and showed strong predictive performance in ROC and regression analyses. These findings suggest that the INHB/FSH ratio may serve as a practical, non-invasive biomarker for estimating testicular pathology severity in NOA patients.

The 5 groups in the trial

  • Early Maturation Arrest (EMA)

    Patients diagnosed with early maturation arrest based on testicular histopathological evaluation.

  • Late Maturation Arrest (LMA)

    Patients diagnosed with late maturation arrest according to histopathological findings.

  • Hypospermatogenesis (HS)

    Patients with histopathologically confirmed hypospermatogenesis.

  • Normospermatogenesis (NS)

    Patients with normal spermatogenesis on histopathological examination.

  • Sertoli Cell-Only Syndrome (SCOS)

    Patients diagnosed with Sertoli cell-only syndrome based on testicular biopsy findings.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Predictive Value of Serum Inhibin B/FSH Ratio in Estimating Pathology Results in Patients Undergoing Micro-TESE Due to Azoospermia
Record updated
17 February 2026